Is metformin a weight loss pill? This is a question many people ask, particularly as interest in medicines for weight management continues to grow in the UK. Metformin is an established oral antidiabetic medicine, licensed primarily for type 2 diabetes mellitus and recommended as first-line treatment by NICE. Whilst some patients notice modest weight changes during treatment, metformin is not licensed by the MHRA as a weight loss medicine. Understanding what metformin is genuinely prescribed for — and what the clinical evidence actually shows — is essential before considering it for any purpose beyond its approved indications.
Summary: Metformin is not a weight loss pill — it is an oral antidiabetic medicine licensed in the UK primarily for type 2 diabetes, and it is not approved by the MHRA for weight management.
- Metformin belongs to the biguanide class and works by reducing hepatic glucose production, improving insulin sensitivity, and slowing intestinal glucose absorption.
- NICE guideline NG28 recommends metformin as first-line pharmacological treatment for type 2 diabetes in adults; it is also used off-label for PCOS under GP or specialist guidance.
- Any weight reduction associated with metformin is modest and variable; it is not consistent across all patients and is not a direct pharmacological target of the medicine.
- Long-term metformin use can reduce vitamin B12 absorption — the MHRA recommends periodic monitoring, particularly in elderly or malnourished patients.
- Metformin is contraindicated in significant renal impairment (eGFR below 30 mL/min/1.73 m²) and must be temporarily stopped during acute illness or before procedures involving iodinated contrast agents.
- Licensed weight management medicines available in the UK include orlistat and semaglutide (Wegovy), which holds a specific NICE-appraised indication for chronic weight management.
Table of Contents
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
What Metformin Is Prescribed For in the UK
Metformin is an oral antidiabetic medicine belonging to the biguanide class. In the UK, it is licensed primarily for the management of type 2 diabetes mellitus, and it remains the first-line pharmacological treatment recommended by the National Institute for Health and Care Excellence (NICE) in guideline NG28 (Type 2 diabetes in adults: management). It works by reducing hepatic glucose production, improving insulin sensitivity in peripheral tissues, and slowing intestinal glucose absorption — collectively helping to lower blood glucose levels without causing the hypoglycaemia associated with some other antidiabetic agents. Full prescribing details, including licensed indications and contraindications, are set out in the Summary of Product Characteristics (SmPC) for individual metformin products (for example, Glucophage), available via the MHRA/Electronic Medicines Compendium (EMC).
It is worth noting that certain metformin products are also licensed for use in children aged 10 years and over with type 2 diabetes, as specified in the relevant SmPC.
Beyond type 2 diabetes, metformin is used off-label in the UK for certain other conditions, most notably polycystic ovary syndrome (PCOS). In PCOS, it helps address insulin resistance, which is a key driver of hormonal imbalance, and may support menstrual regularity and fertility outcomes. NICE guideline NG197 (Polycystic ovary syndrome: diagnosis and management) provides guidance on its use in this context. Metformin does not hold a formal UK licence for PCOS, and its use in this setting should be under specialist or GP guidance with the off-label status clearly discussed with the patient.
It is important to understand that metformin is not licensed as a weight loss medicine in the UK. The Medicines and Healthcare products Regulatory Agency (MHRA) has not approved it for this indication, and it should not be sought or used solely for the purpose of reducing body weight. Its primary therapeutic role remains glycaemic control in the context of type 2 diabetes, and any weight-related effects observed during treatment are considered secondary to its primary mechanism of action rather than a direct pharmacological target.
What the Clinical Evidence Says About Weight Changes
One of the reasons metformin is sometimes associated with weight loss is that, unlike several other antidiabetic medications — such as insulin or sulphonylureas — it is considered weight-neutral to modestly weight-reducing in clinical practice. Some patients with type 2 diabetes do experience a modest reduction in body weight when starting metformin, and this has been observed in clinical trials including the landmark UK Prospective Diabetes Study (UKPDS 34, Lancet 1998), which examined outcomes in overweight patients with type 2 diabetes. Systematic reviews and meta-analyses of randomised controlled trials have broadly confirmed that any weight reduction associated with metformin is modest — typically in the region of 1–3 kg — and is not consistent across all patients.
The mechanisms behind this modest weight effect are not fully established. Several hypotheses have been proposed, though these remain areas of ongoing research:
-
Possible influence on appetite-regulating hormones: Some studies suggest metformin may affect GLP-1 levels, which could contribute to a modest reduction in appetite and caloric intake, though this mechanism has not been definitively confirmed.
-
Gastrointestinal side effects: Nausea, diarrhoea, and abdominal discomfort — common side effects, particularly when starting treatment — may temporarily reduce food intake.
-
Improved insulin sensitivity: By reducing hyperinsulinaemia, metformin may indirectly reduce fat storage, though the clinical significance of this effect on body weight is uncertain.
It is important to note that the weight changes observed are generally modest and variable, and many individuals taking metformin experience no meaningful change in weight at all. The evidence does not support metformin as an effective standalone weight loss intervention in people without diabetes or insulin resistance.
There is no official regulatory approval — from either the MHRA or the European Medicines Agency (EMA) — for metformin as a weight management treatment. Using it outside its licensed indications carries risks and should only occur under careful medical supervision.
Long-term use of metformin can reduce vitamin B12 absorption, which may lead to vitamin B12 deficiency over time. The MHRA Drug Safety Update (June 2022) recommends that patients on long-term metformin — particularly those who are elderly, malnourished, or have symptoms suggestive of deficiency (such as fatigue, numbness, or tingling) — should have their vitamin B12 levels monitored periodically. Patients and prescribers should be aware of this risk. Suspected side effects from metformin or any medicine should be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or via the Yellow Card app.
Who Metformin Is Suitable For on the NHS
On the NHS, metformin is prescribed according to NICE-approved clinical criteria, and eligibility is based on a patient's medical diagnosis rather than a desire to lose weight. The primary groups for whom metformin is considered appropriate include:
-
Adults with type 2 diabetes: NICE guideline NG28 recommends metformin as the first-line treatment when lifestyle interventions alone have not achieved adequate glycaemic control, provided there are no contraindications.
-
People with PCOS: Metformin may be offered by a GP or specialist where insulin resistance is a contributing factor, particularly when fertility treatment or menstrual regulation is being considered, in line with NICE NG197. This remains an off-label use.
-
Individuals at high risk of type 2 diabetes (non-diabetic hyperglycaemia): In some NHS prevention programmes, metformin may be considered off-label for people with non-diabetic hyperglycaemia (previously referred to as 'pre-diabetes', encompassing impaired fasting glucose or impaired glucose tolerance), particularly where intensive lifestyle interventions have been insufficient. NICE guideline PH38 (Preventing type 2 diabetes in people at high risk) sets out the criteria for this approach.
Metformin is contraindicated in certain situations, and a GP will always assess suitability before prescribing. Key contraindications and cautions, as set out in the SmPC, include:
-
Significant renal impairment: Metformin is contraindicated if eGFR is below 30 mL/min/1.73 m² due to the risk of lactic acidosis. It should not be initiated if eGFR is between 30–44 mL/min/1.73 m², and if already prescribed in this range, dose reduction and closer monitoring are required. Renal function should be monitored regularly in all patients taking metformin.
-
Hepatic impairment: Metformin should be avoided in patients with significant liver disease.
-
Acute illness causing dehydration or haemodynamic instability: Metformin should be temporarily stopped during acute illness associated with dehydration (such as severe vomiting, diarrhoea, or fever) — often referred to as sick-day rules — and restarted only when the patient has recovered and renal function has been confirmed as stable.
-
Iodinated contrast media and surgery: Metformin should be temporarily interrupted before or at the time of procedures involving iodinated contrast agents, and before major surgery, with renal function re-checked before restarting. Patients should follow the specific guidance provided by their clinical team.
-
Excessive alcohol intake: Heavy or chronic alcohol use increases the risk of lactic acidosis and should be avoided in patients taking metformin.
-
Lactic acidosis: Although rare, lactic acidosis is a serious potential complication of metformin, most commonly associated with renal impairment, dehydration, or other conditions that reduce tissue oxygenation. Patients should be aware of the symptoms (see below).
Patients should also be aware that metformin is not routinely prescribed for weight loss alone on the NHS. Individuals seeking weight management support through the NHS are typically referred to structured lifestyle programmes. In appropriate cases, licensed weight management medicines may be considered, including orlistat or semaglutide (Wegovy), which holds a specific licence for chronic weight management and has been appraised by NICE in Technology Appraisal TA875. Wegovy is available through specialist NHS weight management (Tier 3) services for eligible patients meeting defined clinical criteria.
When to Speak to Your GP About Weight Management Options
If you are concerned about your weight or are considering metformin as a weight loss option, it is important to speak to your GP rather than seeking medication independently. Self-medicating with prescription medicines — including metformin obtained without a valid prescription — carries significant health risks and is not recommended. Your GP can carry out a thorough assessment, including relevant blood tests, to determine whether any underlying condition such as type 2 diabetes, non-diabetic hyperglycaemia, or PCOS may be contributing to weight gain or difficulty losing weight.
For those seeking NHS support with weight management, your GP can discuss a range of evidence-based options, which may include:
-
Referral to a structured weight management programme, such as those delivered through NHS Tier 2 or Tier 3 services (further information is available at NHS.UK)
-
Dietary and lifestyle advice tailored to your individual circumstances
-
Licensed pharmacological treatments for obesity, where clinically appropriate — for example, orlistat (Xenical) or semaglutide (Wegovy), the latter available through specialist NHS weight management services for patients meeting NICE TA875 criteria
You should contact your GP promptly if you experience any of the following:
-
Unexplained or rapid weight loss, which may indicate an underlying medical condition
-
Symptoms suggestive of diabetes, such as increased thirst, frequent urination, or fatigue
-
Side effects from any current medication that may be affecting your weight
If you are taking metformin and develop any of the following symptoms, seek urgent medical attention immediately, as they may indicate lactic acidosis, a rare but serious side effect: severe nausea or vomiting, abdominal pain, rapid or laboured breathing, muscle cramps, unusual drowsiness, or unexplained fatigue. Do not wait — contact NHS 111 or go to your nearest emergency department.
If you experience any suspected side effects from metformin or any other medicine, you can report these directly to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or using the Yellow Card app.
In summary, whilst metformin may be associated with modest weight changes in certain patient groups, it is not a weight loss pill and should not be used as one. Effective, safe weight management requires a personalised, medically supervised approach — and your GP is the right starting point for that conversation.
Frequently Asked Questions
Can I take metformin just to lose weight if I don't have diabetes?
Metformin is not licensed for weight loss in the UK and should not be taken solely to reduce body weight if you do not have a relevant medical condition such as type 2 diabetes, non-diabetic hyperglycaemia, or PCOS. Using prescription medicines outside their licensed indications without medical supervision carries significant health risks, including serious side effects such as lactic acidosis. If you are concerned about your weight, speak to your GP, who can assess whether any underlying condition is involved and discuss evidence-based, licensed treatment options.
How does metformin differ from actual weight loss medicines like Wegovy?
Metformin is an antidiabetic medicine whose primary purpose is glycaemic control, whereas semaglutide (Wegovy) is specifically licensed by the MHRA for chronic weight management in adults with obesity or overweight with weight-related health conditions. Wegovy has been appraised by NICE in Technology Appraisal TA875 and is available through specialist NHS Tier 3 weight management services for eligible patients. The two medicines work through entirely different mechanisms and are not interchangeable for weight management purposes.
Why do some people seem to lose weight when they start taking metformin?
Some patients experience modest weight reduction with metformin, which may be partly related to gastrointestinal side effects such as nausea reducing food intake, possible effects on appetite-regulating hormones such as GLP-1, or improved insulin sensitivity reducing fat storage. However, these effects are modest, typically in the region of 1–3 kg, and are not seen consistently across all patients. This incidental weight change does not make metformin a weight loss medicine, and it is not effective as a standalone weight loss intervention in people without diabetes or insulin resistance.
Is metformin safe to take long term, and are there any monitoring requirements?
Metformin is generally well tolerated for long-term use, but it does require periodic monitoring, particularly of renal function and vitamin B12 levels. The MHRA Drug Safety Update (June 2022) advises that long-term metformin use can reduce vitamin B12 absorption, and patients who are elderly, malnourished, or symptomatic should have their levels checked regularly. Renal function must also be monitored, as metformin is contraindicated if eGFR falls below 30 mL/min/1.73 m², due to the risk of lactic acidosis.
Can metformin be prescribed for PCOS on the NHS, and will it help with weight?
Metformin can be prescribed off-label for polycystic ovary syndrome (PCOS) on the NHS, particularly where insulin resistance is a contributing factor, in line with NICE guideline NG197. It may help with menstrual regularity and fertility outcomes, but it is not prescribed for PCOS primarily as a weight loss treatment. Any weight-related benefit in PCOS is secondary to its effect on insulin resistance, and its off-label status should be clearly discussed with you by your GP or specialist before starting treatment.
What should I do if I want NHS help with weight management but my GP hasn't mentioned metformin?
If you are seeking weight management support, speak to your GP, who can assess your individual circumstances and refer you to appropriate NHS services such as Tier 2 or Tier 3 structured weight management programmes. Licensed pharmacological treatments for obesity — such as orlistat or semaglutide (Wegovy) — may be considered where clinically appropriate, but metformin would not typically be offered for weight loss alone unless an underlying condition such as type 2 diabetes or non-diabetic hyperglycaemia is identified. Your GP is the right starting point for a personalised, evidence-based weight management plan.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
